04.12.2020 • NewsSterling Pharma

Sterling Pharma Partners ADC Biotechnology

CDMO Sterling Pharma Solutions has formed a strategic partnership with ADC Biotechnology, a UK-based specialist in the discovery, development and manufacture of antibody drug conjugates.

Under the terms of the deal, Sterling will make a “significant” investment in ADC will a view to acquiring the company in quarter one 2021, subject to due diligence.

The businesses will work together to develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high-potency small molecule knowhow.

Sterling’s CEO Kevin Cook said he hoped the partnership’s “combined expertise and targeted investment will be a strong competitive force in the race to find the latest generation of drugs in the oncology area.”

The deal follows Sterling’s purchase in September of a second US development and manufacturing facility in Germantown, Wisconsin, USA, from CDMO Alcami. The new facility bolsters the UK-headquartered CDMO’s presence in the US and provides additional capacity for customer API development and manufacturing projects, especially those with complex and hazardous requirements.

The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities, with specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.

Cook said the US market continues to be a key growth area for Sterling.

Author: Elaine Burridge, Freelance Journalist

CDMO Sterling Pharma Solutions has formed a strategic partnership with ADC...
CDMO Sterling Pharma Solutions has formed a strategic partnership with ADC Biotechnology, a UK-based specialist in antibody drug conjugates. Sterling will make a “significant” investment in ADC will a view to acquiring the company in quarter one 2021. (c) Sterling Pharma Solutions

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.